GlassScriptPhysician profile
Ross W Sullivan
NPI 1366699498
$1,769.79
in general payments reported to CMS, 2019-2025
15 companies · $475 in 2025
The $475 reported for 2025 was more than what 92% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $52.65 · 2021: $257 · 2022: $115 · 2023: $221 · 2024: $506 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $283.30 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $240.00 | 2019-2025 | Invega, Spravato, Invega Sustenna |
| Indivior INC. | $229.02 | 2020-2025 | Perseris, Sublocade |
| Teva Pharmaceuticals USA, INC. | $203.06 | 2023-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $141.02 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Vanda Pharmaceuticals INC. | $129.96 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $106.47 | 2021-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $97.17 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.10 | 2020-2025 | Caplyta |
| Abbvie INC. | $66.59 | 2024-2025 | |
| Gilead Sciences, INC. | $65.43 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $45.80 | 2025 | Cobenfy |
| Orexo US, INC. | $30.91 | 2024-2025 | Zubsolv |
| Hikma Pharmaceuticals USA | $20.81 | 2021 | |
| Braeburn INC. | $18.15 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.